Fintel reports that on January 10, 2025, Truist Securities initiated coverage of BioNTech SE - Depositary Receipt () ...

Asthika Goonewardene, an analyst from Truist Financial, has initiated a new Buy rating on BioNTech SE (BNTX).Stay Ahead of the Market:Discover ...

The BioNTech SE ADR BNTX slipped 3.73% to $122.15 Wednesday, on what proved to be an all-around favorable trading session for ...

NDAQ:VRDN) Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders acquired 4,599 call options on the company. This represents an increase of ...

The BioNTech SE ADR BNTX rose 5.55% to $126.88 Tuesday, on what proved to be an all-around dismal trading session for the ...

Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and ...

Key Insights Significant control over BioNTech by private equity firms implies that the general public has more ...

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.

RNA is a long, polymeric molecule, composed of four different building blocks called nucleotides. In the last decade mRNA has progressed into a promising new class of medicine, with the potential to ...

Genomics is becoming the future of medicine as technological advancements continue to unlock our DNA’s vast potential. Given ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.